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Synthetic peptides corresponding to various regions of the light-activated guanosine 3',5'-cyclic mono- 
phosphate phosphodiesterase (PDE) y-subunit (PDEy) from bovine retinal rod outer segments were synthe- 
sized and tested for their ability to inhibit PDE activity, and GTPase activity of transducin. One of these 
peptides, corresponding to PDEy residues 3145, inhibited PDE activity and GTPase activity in a dose- 
dependent manner. The GTPase activity was inhibited by PDET-3 non-competitively. This region of the 
PDEy subunit may be involved in the direct interaction of transducin and PDEctfl with PDEy. 
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1. INTRODUCTION 
Retinal rod outer segments contain a light- 
activated guanosine 3',5'-cyclic monophosphate 
phosphodiesterase (PDE) which reduces the level 
of cGMP in the rod outer segment in response to 
light [1-3]. Accompanied by the decrease in cGMP 
is a decrease in the Na + conductance of the rod 
outer segment plasma membrane, which hyper- 
polarizes the rod [4]. There is considerable 
evidence suggesting that cGMP is responsible for, 
and directly connected to, the decrease in Na + flux 
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through the rod outer segment plasma membrane 
[4-6]. 
Bovine rod outer segment PDE is made up of 
three subunits. The molecular masses are oe -- 
88 kDa, /~ = 84 kDa and 7 = 11 kDa, as deter- 
mined by SDS-PAGE [7]. The molecular mass 
derived from the amino acid sequence of the 7- 
subunit (9.7 kDa) agrees reasonably well with that 
determined by SDS-PAGE [7,9]. The c~-,/5'- and 7- 
subunits are present in a 1 : 1 : 1 ratio [7]. There is 
some evidence to indicate that the 7-subunit in- 
hibits PDE activity [8]. Trypsin treatment of PDE 
leads to a degradation of the -r-subunit, paralleled 
by an increase in PDE activity [8]. The degree of 
increase in PDE activity is proportional to the 
amount of y-subunit degraded [8]. Addition of 
purified y-subunit o trypsin-treated PDE results 
in a 97% inhibition of PDE activity [8]. 
When PDE is light activated, the Ta, subunit of 
transducin removes the -r-subunit of PDE from the 
or- and fl-subunits of PDE [10]. The Toe subunit 
may bind to the oe- and fl-subunits of PDE, pre- 
venting the 7-subunit from reassociating [11]. 
Recently, the amino acid sequence of the bovine 
7-subunit of PDE has been determined by direct 
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protein sequencing and cDNA sequencing [9]. This 
has enabled us to synthesize peptides corre- 
sponding to various regions of the 3,-subunit. 
These peptides were tested for their ability to in- 
hibit PDE and GTPase activities. Specific inhibi- 
tion studies may help determine which regions of 
the 7-subunit nteract with the oe- and f?-subunits of 
PDE and/or with transducin. 
2. MATERIALS AND METHODS 
Whole bovine eyes were obtained from local 
slaughterhouses. Tris, MgCl2, and other reagents 
were from Sigma. [3H]cGMP (19 Ci/mmol) and 
[7,-32p]GTP (23.8Ci/mmol) were from ICN 
Radiochemicals. The tert-butoxycarbonyl-amino 
acids used for peptide synthesis were from Vega 
Biochemicals and United States Biochemicals 
while other reagents for peptide synthesis were 
HPLC grade from Fisher Scientific. 
2.1. Purification of PDE and transducin 
ROS were purified by discontinuous sucrose 
density-gradient centrifugation u der dim red light 
[12,13]. PDE was extracted by repeated washings 
under bright light with a buffer containing 10 mM 
Tris (pH 7.5), 0.1 mM 2-mercaptoethanol, and 
0.1 mM PMSF. Transducin was recovered by 
repeated washings in the above buffer containing 
10/zM GTP [12,13]. 
2.2. Peptide synthesis and purification 
Peptides were synthesized manually using the 
solid-state method of Hodges and Merrifield [14], 
as modified by Gormann [15] except hat cleavage 
of peptides and protecting roups was performed 
by treatment with HBr and anhydrous 
trifluoroacetic acid [16]. Peptides were purified 
and quantitated as in [12,13,17]. 
2.3. PDE assay 
PDE activity was determined by the method of 
Thompson and Appleman [18]. The final concen- 
trations of the reagents in the incubation mixture 
were 50 mM Tris (pH 7.4), 5 mM MgCI2, 1 mM 
cGMP, 40/~M GTP, and [3H]cGMP 
(150000 cpm/tube, spec. act. 19 Ci/mmol) in a 
final volume of 400/~1. Peptides were added prior 
to addition of substrate. 
2.4. G TPase assay 
The GTPase assay has been described [12]. Pep- 
tides were incubated with GTPase for 5 min before 
the addition of substrate. 
3. RESULTS AND DISCUSSION 
Peptides were synthesized which corresponded 
to various regions of the y-subunit. Each of these 
peptides was tested for its ability to inhibit PDE 
activity. One peptide, PDET-3, was found to in- 
hibit PDE activity in a dose-dependent manner 
(50°70 inhibition at 0.64/zmol/400/~1, see table 1). 
The reason why such a large amount of peptide is 
needed is that very little of the peptide may be in 
the correct conformation. Since these peptides are 
very small segments of proteins, the correct 
3-dimensional structure cannot be maintained as 
well as in the PDE y-subunit, where there are other 
interactions tabilizing the 3-dimensional struc- 
ture. This peptide overlapped an a,-helical region 
predicted by the method of Chou and Fasman [19], 
extending from residues 29-41. A model of this or- 
helical region predicted one surface containing a
large number of positively charged residues (4 
lysines and 2 arginines), while the opposite surface 
contained hydrophobic residues, including 2 
phenylalanines. The model was used to determine 
which amino acids were to be substituted to make 
peptide analogs of PDET-3 (table 1). 
Analog 1 was synthesized with a proline replac- 
ing a more flexible glutamine, at residue 34, to 
break any possible or-helical structure (Chou and 
Fasman prediction). This analog did not inhibit 
PDE activity, suggesting that the less flexible pro- 
line may have altered the secondary structure of 
the or-helix. The hydrophobicity of the peptide was 
not changed significantly by the addition of the 
proline, as determined by Kyte and Doolittle [20], 
suggesting that the loss of inhibitory activity was 
not simply due to a change in the hydrophobicity 
of the peptide. The substitution of a valine for a 
threonine on one of the hydrophilic surfaces, as in 
analog 4, also led to a loss in inhibitory activity. 
This suggested that the hydrophilic nature of this 
surface needed to be maintained for proper in- 
teraction with PDEafl. The replacement of a 
charged residue by an uncharged residue, as in 
analog 3, led to a loss in inhibitory activity, sug- 
gesting that ionic interactions with PDF~fl were 
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Table 1 
Effect of PDE 7 peptides on PDE activity a
Peptide Inhibition at 
0.64/zmol 
per 400/A 
(o70) 
Residue Sequence 
PDE 7-1 26 1 - 14 
PDEy-2 0 16-30 
PDE7-3 50 31-45 
PDE7-4 12 46-60 
PDEy-5 13 61-74 
PDET-6 0 73-87 
Analog 1 0 
Analog 2 0 
Analog 3 0 
Analog 4 0 
c~-Helix 25 29-4 l
Boundary 2 40 35-45 
Met-Asn-Leu-Glu-Pro-Pro-Lys-Ala- 
Glu-Ile-Arg-Ser-Ala-Thr 
Val-Met-Gly-Gly-Pro-Val-Thr-Pro- 
Arg-Lys-Gly-Pro-Pro-Lys-Phe 
Lys-Gln-Arg-Gln-Thr-Arg-Gln-Phe- 
Lys-Ser-Lys-Pro-Pro-Lys-Lys 
Gly-Val-Gln-Gly-Phe-Gly-Asp-Asp-Ile- 
Pro-Gly-Met-Glu-Gly-Leu 
Gly-Thr-Asp-Ile-Thr-Val-Ile-Cys-Pro- 
Trp-Glu-Ala-Phe-Asn 
Phe-Asn-His-Leu-Glu-Leu-His-Glu- 
Leu-Ala-Gln-Tyr-Gly-Ile-Ile 
Lys-Gln-Arg-(Pro)-Thr-Arg-Gln-Phe- 
Lys-Ser-Lys-Pro-Pro-Lys-Lys 
Lys-Gln-Arg-(Glu)-Thr-Arg-Gln-Phe- 
Lys-Ser-Lys-Pro-Pro-Lys-Lys 
Lys-Gln-(Gln)-Gln-Thr-Arg-Gln-Phe- 
Lys-Ser-Lys-Pro-Pro-Lys-Lys 
Lys-Gln-Arg-Gin-(Val)-Arg-Gln-Phe- 
Lys-Ser-Lys-Pro-Pro-Lys-Lys 
Lys-Phe-Lys-Gln-Arg-Gln-Thr-Arg- 
Gln-Phe-Lys-Ser-Lys 
Thr-Arg-Gln-Phe-Lys-Ser-Lys-Pro- 
Pro-Lys-Lys 
a Percent inhibition of PDE activity is expressed as percent of a control without 
added peptide. Results are the average of duplicate xperiments and are as 
described in section 2. In each case, dose-response curves were made 
important. The loss of inhibitory activity in analog 
2, which had a glutamate replacing a glutamine, 
suggests that hydrophobic interactions were also 
important for either the maintenance of the struc- 
ture of the peptide or for interaction with PDEcrB. 
Thus it appeared that the intact structure of the a~- 
helix was important for the peptide to recognize 
PDE~' ,  as several kinds of substitutions were all 
deleterious. 
To determine the optimal sequence for interac- 
tion, a boundary peptide was synthesized (table 1). 
PDE7 boundary 2 inhibited PDE activity. PDE7 
or-helix, a peptide corresponding to the a-helical 
region extending from amino acids 29-41, also in- 
hibited PDE activity to some extent (2407c inhibi- 
tion at 0.64/~mol/400/A). 
The or-helical region is flanked by prolines and 
lysines. It is clear that these lysines and prolines are 
important for optimal interaction. This is shown 
by the ability of PDEy boundary 2 to inhibit PDE 
activity while PDEy or-helix, which lacks the pro- 
lines and lysines, does not inhibit PDE activity as 
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well. These flanking regions could serve as recogni- 
tion points, or to maintain a certain secondary 
structure. 
To determine whether the PDE7 peptides had 
any effect on transducin a GTPase assay was per- 
formed. Addition of PDET-3 inhibited the GTPase 
activity of transducin in a dose-dependent manner 
(fig.l) with 50% inhibition occurring at about 
0.12/~mol peptide in a 100/~l assay. Kinetic studies 
were performed to determine the nature of the in- 
teraction of PDET-3 with transducin (fig.2). The 
addition of 0.076/~mol PDE-r-3 decreased the Vmx 
from 9.15 to 5.20/~M/min while the Km was unaf- 
fected showing that PDET-3 is a non-competitive 
inhibitor of GTPase activity. 
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Fig. 1. Effect of PDE-r-3 on GTPase activity. Percent 
inhibition is expressed as percent of a control without 
peptide. Results are the average of triplicate xperiments 
(_+ SE) and are as described in section 2. 
2.6_ 
2.4. 
2.2. t- - +PDEY-3 / ~  
2.0. I"1 - - PolsT-3 
1.8. 
-~ +.s. 
1.4. ~ 
~ 1,2. 
-" i.o. 
0.8. 
0.6. 
0.4. 
I l IGTPI  (~M) 
Fig.2. Kinetic studies of PDEy-3 on GTPase activity. 
The GTPase assay is described in section 2. Peptide 
(0.076~mol per 100~1 assay) was added to the 
appropriate samples 5 min prior to the addition of 
substrate. Results are the average of duplicate 
experiments. Straight lines were plotted by analysing the 
data with a linear regression program. 
The above results suggest that PDE-r may be in- 
volved in more than the direct regulation of PDE 
activity. PDE7 may be involved in the regulation 
of transducin either directly or indirectly. The 
decrease in GTPase activity could be due to a 
decrease in hydrolysis rate, a slower dissociation of 
GDP or a slower association of GTP to Ta~. This 
could be achieved in several ways. PDE7 could 
bind to Tt~ and inhibit its reassociation with the B- 
and 7-subunits of transducin (T~'7). Conversely, 
PDE 7 could also bind to Tj87, preventing 
reassociation with Tcr, or with rhodopsin. In each 
of  these cases, transducin would not be able to 
bind to rhodopsin. Also, PDE 7 could regulate 
GTPase activity without affecting the binding of 
Ta, with T~' 7. Further investigation is required to 
determine the role of PDE7 in the visual transduc- 
tion cascade. We are currently looking at 
GMPP(NH)P binding and GDP binding to deter- 
mine the regulatory mechanism by which PDE7 af- 
fects transducin. 
ACKNOWLEDGEMENT 
This research was supported by a grant from 
NIH, EY05623 to D.J.T. 
269 
Volume 222, number 2 FEBS LETTERS October 1987 
REFERENCES 
[1] Bitensky, M.W., Gorman, R.E. and Miller, W.H. 
(1971) Proc. Natl. Acad. Sci. USA 68, 561-565. 
[2] Cote, R.H., Bierbaum, M.S., Nicol, G.D. and 
Bownds, M.D. (1984) J. Biol. Chem. 259, 
9635-9641. 
[31 Nicol, G.D. and Miller, W.H. (1978) Proc. Natl. 
Acad. Sci. USA 75, 5217-5220. 
[4] Fesenko, E.E., Kolesnikov, S.S. and Lyvbarsky, 
A.L. (1985) Nature 313, 310-313. 
[5] Cook, N., Zeilinger, C., Koch, K. and Kaup, B. 
(1986) J. Biol. Chem. 261, 17033-17039. 
[6] Cook, N., Hanke, W. and Kaup, B. (1987) Proc. 
Natl. Acad. Sci. USA 84, 585-589. 
[7] Baehr, W., Devlin, M.J. and Applebury, M.L. 
(1979) J. Biol. Chem. 254, 11669-11677. 
[8] Hurley, J.B. and Stryer, L. (1982) J. Biol. Chem. 
257, 11094-11099. 
[9] Ovchinnikov, Y.A., Lipkin, V.M., Kumarev, V.P., 
Gubanov, V.V., Khramstov, N.V., Akhmedov, 
N.B., Zagranichny, V.E. and Muradov, K.G. 
(1986) FEBS Lett. 204, 288-292. 
[10] Fung, B.K.-K., Hurley, J.B. and Stryer, L. (1981) 
Proc. Natl. Acad. Sci. USA 78, 152-156. 
[11] Sitaramayya, A., Harkness, J., Parkes, J.H., 
Gonzalez-Olivia, C. and Liebman, P.A. (1986) 
Biochemistry 25, 651-656. 
[12] Takemoto, D.J., Morrison, D., Davis, L.C. and 
Takemoto, L.J. (1986) Biochem. J. 235, 309-312. 
[131 Takemoto, D.J., Takemoto, L.J., Hansen, J. and 
Morrison, D. (1985) Biochem. J. 232, 669-672. 
[141 Hodges, R.S. and Merrifield, R.B. (1975) Anal. 
Biochem. 65,241-272. 
[15] Gormann, J.J. (1984) Anal. Biochem. 136, 
397-406. 
[16] Merrifield, R.B. (1964) Biochemistry 3, 1385-1390. 
[17] Lookhart, G.L., Jones, B.L., Cooper, D.B. and 
Hall, S.B. (1982) J. Biochem. Biophys. Methods 7, 
15-23. 
[18] Thompson, W.J. and Appleman, M.M. (1971) 
Biochemistry 10, 311-316. 
[19] Chou, P.Y. and Fasman, G.D. (1978) Annu. Rev. 
Biochem. 47, 251-276. 
[20] Kyte, J. and Doolittle, R.F. (1982) J. Mol. Biol. 
157, 105-132. 
270 
